Drugs / BPX-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00868595 | Apr 2009 → Jul 2011 | castration-resistant prostate carcinoma | Bellicum Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00868595 ↗ |
| Known as | BP-GMAX-CD1 | “therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1), plus activating agent, AP1903, in patients with castrate resistant prostate cancer.” NCT00868595 ↗ |
| Modality | Vaccine | “therapeutic vaccine, BPX-101” NCT00868595 ↗ |